Antibodies for VEGF and Lung Cancer Research

July 14, 2015 - PRLog -- The vascular endothelial growth factor (VEGF) pathway plays a pivotal role in angiogenesis and is associated with a variety of human cancers, including non-small-cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC).

In the tumor milieu, high expression of VEGF leads to abnormal angiogenic signaling and creates atypical blood vessels that often compromise delivery of therapeutic drugs. The VEGF pathway induces the release of proteases into the extracellular matrix, inhibits dendritic cells, and loosens the connection between endothelial cells, thus creating an environment where tumor cells can migrate, proliferate, and survive. Because of its role in enhancing the invasive and metastatic potential of cancer cells, the VEGF pathway is an important target for lung cancer research and chemotherapeutic drug development.

GeneTex offers a large selection of VEGF and VEGF-related antibodies, many of which are validated for multiple applications. Please see below to view a panel of our most highly regarded VEGF and VEGF-related antibodies and consider whether these reagents can accelerate your research.

Please see: http://www.genetex.com/Web/News/Antibodies-for-VEGF-and-L...